78 results
S-3ASR
EX-4.3
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
to Section 13 or Section 15(d) of the Exchange Act; provided, however, the Company shall not be required to deliver to the Trustee any materials for which
S-3ASR
EX-4.2
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
) of the Exchange Act; provided, however, the Company shall not be required to deliver to the Trustee any materials for which the Company has sought and received
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
Additional Materials
☐ Soliciting Material Pursuant to §240.14a-12
AKERO THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name … previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1
8-K
EX-1.1
2w9aiy smvamz96z
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
8pug ux6g
6 Mar 24
Entry into a Material Definitive Agreement
5:25pm
8-K
met1r8qi
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
sglvsydywntcq340ex
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
zo6z3l
5 Jun 23
Results of Operations and Financial Condition
8:05am
8-K
EX-1.1
mzy qnf4bqvj1b
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
6a4x fbkc69om7u7zn
17 May 23
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
5:01pm
8-K
necfm
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-1.1
e3canfj
16 Sep 22
Entry into a Material Definitive Agreement
4:02pm